Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Phase 1 Completed 42 enrolled University of Chicago Corcept Therapeutics · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).

Timeline

Start: 2018-10-23
Primary completion: 2024-06-10
Completion: 2024-06-10

Outcome

Missed primary endpoint

paper Enzalutamide combined with mifepristone was safe and well tolerated but did not meet its primary endpoint. PMID 35110415 ↗

Publications

Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, Schonhoft J, Chu YL, Karrison T, Stadler WM, Szmulewitz RZ. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 Apr 14;28(8):1549-1559. doi: 10.1158/1078-0432.CCR-21-4049.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enzalutamide	Other / unclassified	—	Oral
Subject	Relacorilant	Small molecule	—	Oral